nodes	percent_of_prediction	percent_of_DWPC	metapath
Nafarelin—Gonadotropin Releasing Hormone Receptor Agonists—Goserelin—prostate cancer	0.332	1	CiPCiCtD
Nafarelin—Degarelix—prostate cancer	0.155	0.601	CrCtD
Nafarelin—GNRHR—Degarelix—prostate cancer	0.124	0.635	CbGbCtD
Nafarelin—Goserelin—prostate cancer	0.103	0.398	CrCtD
Nafarelin—GNRHR—Goserelin—prostate cancer	0.0711	0.365	CbGbCtD
Nafarelin—Cetrorelix—Degarelix—prostate cancer	0.0268	0.161	CrCrCtD
Nafarelin—Ceruletide—Degarelix—prostate cancer	0.0232	0.139	CrCrCtD
Nafarelin—Goserelin—Degarelix—prostate cancer	0.0205	0.123	CrCrCtD
Nafarelin—Pentagastrin—Goserelin—prostate cancer	0.0178	0.106	CrCrCtD
Nafarelin—Degarelix—Goserelin—prostate cancer	0.0178	0.106	CrCrCtD
Nafarelin—Cetrorelix—Goserelin—prostate cancer	0.0178	0.106	CrCrCtD
Nafarelin—Gonadorelin—Degarelix—prostate cancer	0.0168	0.1	CrCrCtD
Nafarelin—Ceruletide—Goserelin—prostate cancer	0.0154	0.092	CrCrCtD
Nafarelin—Gonadorelin—Goserelin—prostate cancer	0.0111	0.0665	CrCrCtD
Nafarelin—GNRHR—Hormone ligand-binding receptors—GNRH1—prostate cancer	0.000819	0.132	CbGpPWpGaD
Nafarelin—GNRHR—Peptide GPCRs—GRPR—prostate cancer	0.000265	0.0429	CbGpPWpGaD
Nafarelin—GNRHR—GPCRs, Other—GRPR—prostate cancer	0.000225	0.0363	CbGpPWpGaD
Nafarelin—GNRHR—Peptide GPCRs—MC2R—prostate cancer	0.000218	0.0352	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—GRPR—prostate cancer	0.000126	0.0204	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GRPR—prostate cancer	0.000113	0.0183	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—RLN2—prostate cancer	9.5e-05	0.0154	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—GRPR—prostate cancer	8.37e-05	0.0135	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—GNRH1—prostate cancer	7.86e-05	0.0127	CbGpPWpGaD
Nafarelin—GNRHR—GPCRs, Other—ADRB2—prostate cancer	7.82e-05	0.0126	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—LPAR1—prostate cancer	7.62e-05	0.0123	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—GRP—prostate cancer	7.62e-05	0.0123	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—PLCB2—prostate cancer	7.54e-05	0.0122	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—RLN2—prostate cancer	7.24e-05	0.0117	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GNRH1—prostate cancer	7.03e-05	0.0114	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—MC2R—prostate cancer	6.87e-05	0.0111	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—GNG5—prostate cancer	6.84e-05	0.0111	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—LPAR1—prostate cancer	6.81e-05	0.011	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GRP—prostate cancer	6.81e-05	0.011	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PLCB2—prostate cancer	6.74e-05	0.0109	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—GRPR—prostate cancer	6.37e-05	0.0103	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—PENK—prostate cancer	6.12e-05	0.00989	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GNG5—prostate cancer	6.12e-05	0.00988	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—ANXA1—prostate cancer	5.6e-05	0.00905	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—WNT4—prostate cancer	5.49e-05	0.00886	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—OR51E2—prostate cancer	5.4e-05	0.00872	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—MC2R—prostate cancer	5.23e-05	0.00845	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—GNRH1—prostate cancer	5.21e-05	0.00841	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—LPAR1—prostate cancer	5.04e-05	0.00815	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—GRP—prostate cancer	5.04e-05	0.00815	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—ANXA1—prostate cancer	5.01e-05	0.0081	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—OR51E2—prostate cancer	4.9e-05	0.00792	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CX3CL1—prostate cancer	4.9e-05	0.00791	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—PRKCQ—prostate cancer	4.68e-05	0.00755	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—PENK—prostate cancer	4.66e-05	0.00753	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—RGS17—prostate cancer	4.59e-05	0.00741	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PRKCQ—prostate cancer	4.18e-05	0.00676	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—RGS17—prostate cancer	4.17e-05	0.00673	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—ITPR1—prostate cancer	4.16e-05	0.00672	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—RLN2—prostate cancer	4.09e-05	0.00661	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—GNRH1—prostate cancer	3.97e-05	0.00641	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—LPAR1—prostate cancer	3.84e-05	0.0062	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—GRP—prostate cancer	3.84e-05	0.0062	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—PLXNB1—prostate cancer	3.74e-05	0.00604	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CX3CL1—prostate cancer	3.73e-05	0.00602	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—ITPR1—prostate cancer	3.72e-05	0.00601	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—RLN2—prostate cancer	3.71e-05	0.006	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—ANXA1—prostate cancer	3.71e-05	0.00599	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—GRPR—prostate cancer	3.6e-05	0.00582	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—GNG5—prostate cancer	3.45e-05	0.00557	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PLXNB1—prostate cancer	3.4e-05	0.00549	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL12—prostate cancer	3.39e-05	0.00548	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—GRPR—prostate cancer	3.27e-05	0.00528	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—PTHLH—prostate cancer	3.01e-05	0.00486	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—MC2R—prostate cancer	2.96e-05	0.00478	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—ADRB2—prostate cancer	2.91e-05	0.0047	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—OR51E2—prostate cancer	2.9e-05	0.00468	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—ANXA1—prostate cancer	2.83e-05	0.00456	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—WNT4—prostate cancer	2.81e-05	0.00455	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—MC2R—prostate cancer	2.69e-05	0.00434	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—BMPR1B—prostate cancer	2.65e-05	0.00428	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CALCA—prostate cancer	2.65e-05	0.00427	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—PENK—prostate cancer	2.64e-05	0.00426	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CXCL12—prostate cancer	2.58e-05	0.00418	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—RGS17—prostate cancer	2.46e-05	0.00398	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PENK—prostate cancer	2.39e-05	0.00387	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MAP2K1—prostate cancer	2.28e-05	0.00369	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—VIP—prostate cancer	2.24e-05	0.00362	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—GNRH1—prostate cancer	2.24e-05	0.00362	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—ADRB2—prostate cancer	2.22e-05	0.00358	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—RLN2—prostate cancer	2.19e-05	0.00354	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—GRP—prostate cancer	2.17e-05	0.00351	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—LPAR1—prostate cancer	2.17e-05	0.00351	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—PLCB2—prostate cancer	2.15e-05	0.00347	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—HSD17B1—prostate cancer	2.09e-05	0.00338	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CTBP2—prostate cancer	2.09e-05	0.00338	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—JAK2—prostate cancer	2.08e-05	0.00336	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—PDE4D—prostate cancer	2.05e-05	0.00331	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—GNRH1—prostate cancer	2.04e-05	0.00329	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—VIP—prostate cancer	2.04e-05	0.00329	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PLXNB1—prostate cancer	2.01e-05	0.00324	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—LPAR1—prostate cancer	1.97e-05	0.00318	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—GRP—prostate cancer	1.97e-05	0.00318	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PLCB2—prostate cancer	1.95e-05	0.00315	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—GNG5—prostate cancer	1.95e-05	0.00315	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—GRPR—prostate cancer	1.93e-05	0.00312	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CX3CL1—prostate cancer	1.91e-05	0.00309	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—IL17RD—prostate cancer	1.87e-05	0.00301	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PDE4D—prostate cancer	1.86e-05	0.00301	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—GNG5—prostate cancer	1.77e-05	0.00286	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—PTHLH—prostate cancer	1.7e-05	0.00274	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—JUP—prostate cancer	1.66e-05	0.00269	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—WNT4—prostate cancer	1.66e-05	0.00269	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—ANXA1—prostate cancer	1.6e-05	0.00258	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—RALBP1—prostate cancer	1.59e-05	0.00256	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MC2R—prostate cancer	1.59e-05	0.00256	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PTHLH—prostate cancer	1.54e-05	0.00249	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PRKACB—prostate cancer	1.51e-05	0.00244	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—CALCA—prostate cancer	1.5e-05	0.00242	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PPP3CA—prostate cancer	1.47e-05	0.00238	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—CXCL12—prostate cancer	1.46e-05	0.00236	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—ANXA1—prostate cancer	1.45e-05	0.00234	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PENK—prostate cancer	1.41e-05	0.00228	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL8—prostate cancer	1.41e-05	0.00227	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—prostate cancer	1.39e-05	0.00224	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CALCA—prostate cancer	1.36e-05	0.00219	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—GHR—prostate cancer	1.35e-05	0.00218	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—PIK3CA—prostate cancer	1.35e-05	0.00218	CbGpPWpGaD
Nafarelin—Asthenia—Goserelin—prostate cancer	1.34e-05	0.000315	CcSEcCtD
Nafarelin—Insomnia—Estradiol—prostate cancer	1.34e-05	0.000315	CcSEcCtD
Nafarelin—Cerebrovascular accident—Epirubicin—prostate cancer	1.34e-05	0.000314	CcSEcCtD
Nafarelin—Hyperhidrosis—Mitoxantrone—prostate cancer	1.34e-05	0.000313	CcSEcCtD
Nafarelin—Paraesthesia—Estradiol—prostate cancer	1.33e-05	0.000312	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—PRKCQ—prostate cancer	1.33e-05	0.00215	CbGpPWpGaD
Nafarelin—Asthenia—Conjugated Estrogens—prostate cancer	1.33e-05	0.000312	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—CXCL12—prostate cancer	1.33e-05	0.00214	CbGpPWpGaD
Nafarelin—Pruritus—Goserelin—prostate cancer	1.32e-05	0.000311	CcSEcCtD
Nafarelin—Dyspnoea—Estradiol—prostate cancer	1.32e-05	0.00031	CcSEcCtD
Nafarelin—Weight increased—Prednisone—prostate cancer	1.32e-05	0.000309	CcSEcCtD
Nafarelin—Anorexia—Mitoxantrone—prostate cancer	1.32e-05	0.000309	CcSEcCtD
Nafarelin—Pruritus—Conjugated Estrogens—prostate cancer	1.31e-05	0.000308	CcSEcCtD
Nafarelin—Weight decreased—Prednisone—prostate cancer	1.31e-05	0.000307	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—prostate cancer	1.31e-05	0.00212	CbGpPWpGaD
Nafarelin—Rhinitis—Capecitabine—prostate cancer	1.31e-05	0.000306	CcSEcCtD
Nafarelin—Hot flush—Doxorubicin—prostate cancer	1.3e-05	0.000304	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—NRP1—prostate cancer	1.29e-05	0.00209	CbGpPWpGaD
Nafarelin—Increased appetite—Doxorubicin—prostate cancer	1.29e-05	0.000303	CcSEcCtD
Nafarelin—Affect lability—Epirubicin—prostate cancer	1.29e-05	0.000303	CcSEcCtD
Nafarelin—Decreased appetite—Estradiol—prostate cancer	1.29e-05	0.000302	CcSEcCtD
Nafarelin—Depression—Prednisone—prostate cancer	1.29e-05	0.000302	CcSEcCtD
Nafarelin—Menopausal symptoms—Doxorubicin—prostate cancer	1.29e-05	0.000302	CcSEcCtD
Nafarelin—Diarrhoea—Goserelin—prostate cancer	1.28e-05	0.0003	CcSEcCtD
Nafarelin—Acute coronary syndrome—Prednisone—prostate cancer	1.27e-05	0.000299	CcSEcCtD
Nafarelin—Constipation—Estradiol—prostate cancer	1.27e-05	0.000298	CcSEcCtD
Nafarelin—Diarrhoea—Conjugated Estrogens—prostate cancer	1.27e-05	0.000297	CcSEcCtD
Nafarelin—Myocardial infarction—Prednisone—prostate cancer	1.27e-05	0.000297	CcSEcCtD
Nafarelin—Vertigo—Etoposide—prostate cancer	1.27e-05	0.000297	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Mitoxantrone—prostate cancer	1.26e-05	0.000295	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—ADRB2—prostate cancer	1.25e-05	0.00202	CbGpPWpGaD
Nafarelin—Mood swings—Epirubicin—prostate cancer	1.24e-05	0.000291	CcSEcCtD
Nafarelin—Paraesthesia—Mitoxantrone—prostate cancer	1.24e-05	0.000291	CcSEcCtD
Nafarelin—Cerebrovascular accident—Doxorubicin—prostate cancer	1.24e-05	0.00029	CcSEcCtD
Nafarelin—Dizziness—Goserelin—prostate cancer	1.24e-05	0.00029	CcSEcCtD
Nafarelin—Dyspnoea—Mitoxantrone—prostate cancer	1.23e-05	0.000289	CcSEcCtD
Nafarelin—Dizziness—Conjugated Estrogens—prostate cancer	1.23e-05	0.000287	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—VAV3—prostate cancer	1.22e-05	0.00197	CbGpPWpGaD
Nafarelin—Convulsion—Etoposide—prostate cancer	1.22e-05	0.000286	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—PRKCQ—prostate cancer	1.21e-05	0.00196	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—prostate cancer	1.2e-05	0.00195	CbGpPWpGaD
Nafarelin—Dry skin—Epirubicin—prostate cancer	1.2e-05	0.000282	CcSEcCtD
Nafarelin—Decreased appetite—Mitoxantrone—prostate cancer	1.2e-05	0.000282	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—GNRH1—prostate cancer	1.2e-05	0.00194	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—VIP—prostate cancer	1.2e-05	0.00194	CbGpPWpGaD
Nafarelin—Chest pain—Etoposide—prostate cancer	1.2e-05	0.000281	CcSEcCtD
Nafarelin—Affect lability—Doxorubicin—prostate cancer	1.19e-05	0.00028	CcSEcCtD
Nafarelin—Vomiting—Goserelin—prostate cancer	1.19e-05	0.000279	CcSEcCtD
Nafarelin—Alopecia—Docetaxel—prostate cancer	1.19e-05	0.000279	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—ITPR1—prostate cancer	1.19e-05	0.00191	CbGpPWpGaD
Nafarelin—Constipation—Mitoxantrone—prostate cancer	1.18e-05	0.000277	CcSEcCtD
Nafarelin—Rash—Goserelin—prostate cancer	1.18e-05	0.000277	CcSEcCtD
Nafarelin—Dermatitis—Goserelin—prostate cancer	1.18e-05	0.000276	CcSEcCtD
Nafarelin—Vomiting—Conjugated Estrogens—prostate cancer	1.18e-05	0.000276	CcSEcCtD
Nafarelin—Urticaria—Estradiol—prostate cancer	1.18e-05	0.000276	CcSEcCtD
Nafarelin—Mental disorder—Docetaxel—prostate cancer	1.18e-05	0.000276	CcSEcCtD
Nafarelin—Headache—Goserelin—prostate cancer	1.17e-05	0.000275	CcSEcCtD
Nafarelin—Malnutrition—Docetaxel—prostate cancer	1.17e-05	0.000275	CcSEcCtD
Nafarelin—Rash—Conjugated Estrogens—prostate cancer	1.17e-05	0.000274	CcSEcCtD
Nafarelin—Dermatitis—Conjugated Estrogens—prostate cancer	1.17e-05	0.000274	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—GRP—prostate cancer	1.16e-05	0.00188	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—LPAR1—prostate cancer	1.16e-05	0.00188	CbGpPWpGaD
Nafarelin—Headache—Conjugated Estrogens—prostate cancer	1.16e-05	0.000272	CcSEcCtD
Nafarelin—Gastritis—Epirubicin—prostate cancer	1.16e-05	0.000272	CcSEcCtD
Nafarelin—Muscular weakness—Epirubicin—prostate cancer	1.16e-05	0.000271	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—LRP2—prostate cancer	1.15e-05	0.00186	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PLCB2—prostate cancer	1.15e-05	0.00186	CbGpPWpGaD
Nafarelin—Alopecia—Capecitabine—prostate cancer	1.15e-05	0.00027	CcSEcCtD
Nafarelin—Mood swings—Doxorubicin—prostate cancer	1.15e-05	0.00027	CcSEcCtD
Nafarelin—Dysgeusia—Docetaxel—prostate cancer	1.15e-05	0.000269	CcSEcCtD
Nafarelin—Abdominal distension—Epirubicin—prostate cancer	1.14e-05	0.000268	CcSEcCtD
Nafarelin—Mental disorder—Capecitabine—prostate cancer	1.14e-05	0.000268	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—ADRB2—prostate cancer	1.14e-05	0.00184	CbGpPWpGaD
Nafarelin—Malnutrition—Capecitabine—prostate cancer	1.13e-05	0.000266	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—P4HB—prostate cancer	1.13e-05	0.00183	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CX3CL1—prostate cancer	1.13e-05	0.00183	CbGpPWpGaD
Nafarelin—Dry skin—Doxorubicin—prostate cancer	1.11e-05	0.000261	CcSEcCtD
Nafarelin—Nausea—Goserelin—prostate cancer	1.11e-05	0.000261	CcSEcCtD
Nafarelin—Hyperhidrosis—Etoposide—prostate cancer	1.11e-05	0.000261	CcSEcCtD
Nafarelin—Dysgeusia—Capecitabine—prostate cancer	1.11e-05	0.00026	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—VAV3—prostate cancer	1.11e-05	0.00179	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—HIST1H2BG—prostate cancer	1.11e-05	0.00179	CbGpPWpGaD
Nafarelin—Nausea—Conjugated Estrogens—prostate cancer	1.1e-05	0.000258	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—GRB7—prostate cancer	1.1e-05	0.00178	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PDE4D—prostate cancer	1.1e-05	0.00178	CbGpPWpGaD
Nafarelin—Urticaria—Mitoxantrone—prostate cancer	1.1e-05	0.000258	CcSEcCtD
Nafarelin—Anorexia—Etoposide—prostate cancer	1.1e-05	0.000257	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—ITPR1—prostate cancer	1.08e-05	0.00174	CbGpPWpGaD
Nafarelin—Gastritis—Doxorubicin—prostate cancer	1.07e-05	0.000252	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—HIST1H4H—prostate cancer	1.07e-05	0.00173	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CXCL8—prostate cancer	1.07e-05	0.00173	CbGpPWpGaD
Nafarelin—Muscular weakness—Doxorubicin—prostate cancer	1.07e-05	0.000251	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—prostate cancer	1.07e-05	0.00172	CbGpPWpGaD
Nafarelin—Asthenia—Estradiol—prostate cancer	1.06e-05	0.00025	CcSEcCtD
Nafarelin—Dysuria—Epirubicin—prostate cancer	1.06e-05	0.000249	CcSEcCtD
Nafarelin—Abdominal distension—Doxorubicin—prostate cancer	1.06e-05	0.000248	CcSEcCtD
Nafarelin—Pruritus—Estradiol—prostate cancer	1.05e-05	0.000246	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—GNG5—prostate cancer	1.05e-05	0.00169	CbGpPWpGaD
Nafarelin—Palpitations—Docetaxel—prostate cancer	1.04e-05	0.000243	CcSEcCtD
Nafarelin—Paraesthesia—Etoposide—prostate cancer	1.03e-05	0.000242	CcSEcCtD
Nafarelin—Weight increased—Epirubicin—prostate cancer	1.03e-05	0.000242	CcSEcCtD
Nafarelin—Weight decreased—Epirubicin—prostate cancer	1.03e-05	0.00024	CcSEcCtD
Nafarelin—Dyspnoea—Etoposide—prostate cancer	1.03e-05	0.00024	CcSEcCtD
Nafarelin—Alopecia—Prednisone—prostate cancer	1.03e-05	0.00024	CcSEcCtD
Nafarelin—Vertigo—Capecitabine—prostate cancer	1.02e-05	0.000239	CcSEcCtD
Nafarelin—Mental disorder—Prednisone—prostate cancer	1.02e-05	0.000238	CcSEcCtD
Nafarelin—Diarrhoea—Estradiol—prostate cancer	1.02e-05	0.000238	CcSEcCtD
Nafarelin—Convulsion—Docetaxel—prostate cancer	1.01e-05	0.000238	CcSEcCtD
Nafarelin—Malnutrition—Prednisone—prostate cancer	1.01e-05	0.000237	CcSEcCtD
Nafarelin—Palpitations—Capecitabine—prostate cancer	1e-05	0.000235	CcSEcCtD
Nafarelin—Decreased appetite—Etoposide—prostate cancer	1e-05	0.000234	CcSEcCtD
Nafarelin—Myalgia—Docetaxel—prostate cancer	9.97e-06	0.000234	CcSEcCtD
Nafarelin—Chest pain—Docetaxel—prostate cancer	9.97e-06	0.000234	CcSEcCtD
Nafarelin—Arthralgia—Docetaxel—prostate cancer	9.97e-06	0.000234	CcSEcCtD
Nafarelin—Asthenia—Mitoxantrone—prostate cancer	9.92e-06	0.000233	CcSEcCtD
Nafarelin—Constipation—Etoposide—prostate cancer	9.84e-06	0.000231	CcSEcCtD
Nafarelin—Conjunctivitis—Epirubicin—prostate cancer	9.83e-06	0.00023	CcSEcCtD
Nafarelin—Dizziness—Estradiol—prostate cancer	9.82e-06	0.00023	CcSEcCtD
Nafarelin—Dysuria—Doxorubicin—prostate cancer	9.81e-06	0.00023	CcSEcCtD
Nafarelin—Chest pain—Capecitabine—prostate cancer	9.66e-06	0.000226	CcSEcCtD
Nafarelin—Myalgia—Capecitabine—prostate cancer	9.66e-06	0.000226	CcSEcCtD
Nafarelin—Arthralgia—Capecitabine—prostate cancer	9.66e-06	0.000226	CcSEcCtD
Nafarelin—Oedema—Docetaxel—prostate cancer	9.56e-06	0.000224	CcSEcCtD
Nafarelin—Weight increased—Doxorubicin—prostate cancer	9.55e-06	0.000224	CcSEcCtD
Nafarelin—Epistaxis—Epirubicin—prostate cancer	9.54e-06	0.000224	CcSEcCtD
Nafarelin—Weight decreased—Doxorubicin—prostate cancer	9.49e-06	0.000223	CcSEcCtD
Nafarelin—Sinusitis—Epirubicin—prostate cancer	9.49e-06	0.000222	CcSEcCtD
Nafarelin—Diarrhoea—Mitoxantrone—prostate cancer	9.46e-06	0.000222	CcSEcCtD
Nafarelin—Vomiting—Estradiol—prostate cancer	9.44e-06	0.000221	CcSEcCtD
Nafarelin—Shock—Docetaxel—prostate cancer	9.41e-06	0.00022	CcSEcCtD
Nafarelin—Rash—Estradiol—prostate cancer	9.36e-06	0.000219	CcSEcCtD
Nafarelin—Dermatitis—Estradiol—prostate cancer	9.35e-06	0.000219	CcSEcCtD
Nafarelin—Headache—Estradiol—prostate cancer	9.3e-06	0.000218	CcSEcCtD
Nafarelin—Oedema—Capecitabine—prostate cancer	9.26e-06	0.000217	CcSEcCtD
Nafarelin—Urticaria—Etoposide—prostate cancer	9.14e-06	0.000214	CcSEcCtD
Nafarelin—Anorexia—Docetaxel—prostate cancer	9.11e-06	0.000214	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—PTHLH—prostate cancer	9.11e-06	0.00147	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—TGFBR1—prostate cancer	9.11e-06	0.00147	CbGpPWpGaD
Nafarelin—Shock—Capecitabine—prostate cancer	9.11e-06	0.000213	CcSEcCtD
Nafarelin—Rhinitis—Epirubicin—prostate cancer	9.1e-06	0.000213	CcSEcCtD
Nafarelin—Conjunctivitis—Doxorubicin—prostate cancer	9.09e-06	0.000213	CcSEcCtD
Nafarelin—Vertigo—Prednisone—prostate cancer	9.08e-06	0.000213	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—AKR1C3—prostate cancer	8.96e-06	0.00145	CbGpPWpGaD
Nafarelin—Hyperhidrosis—Capecitabine—prostate cancer	8.95e-06	0.00021	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—PRKACB—prostate cancer	8.92e-06	0.00144	CbGpPWpGaD
Nafarelin—Epistaxis—Doxorubicin—prostate cancer	8.82e-06	0.000207	CcSEcCtD
Nafarelin—Anorexia—Capecitabine—prostate cancer	8.82e-06	0.000207	CcSEcCtD
Nafarelin—Nausea—Estradiol—prostate cancer	8.82e-06	0.000207	CcSEcCtD
Nafarelin—Vomiting—Mitoxantrone—prostate cancer	8.79e-06	0.000206	CcSEcCtD
Nafarelin—Sinusitis—Doxorubicin—prostate cancer	8.78e-06	0.000206	CcSEcCtD
Nafarelin—Convulsion—Prednisone—prostate cancer	8.75e-06	0.000205	CcSEcCtD
Nafarelin—Rash—Mitoxantrone—prostate cancer	8.72e-06	0.000204	CcSEcCtD
Nafarelin—Dermatitis—Mitoxantrone—prostate cancer	8.71e-06	0.000204	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Docetaxel—prostate cancer	8.71e-06	0.000204	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—PPP3CA—prostate cancer	8.69e-06	0.0014	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—THBS1—prostate cancer	8.69e-06	0.0014	CbGpPWpGaD
Nafarelin—Headache—Mitoxantrone—prostate cancer	8.66e-06	0.000203	CcSEcCtD
Nafarelin—Insomnia—Docetaxel—prostate cancer	8.65e-06	0.000203	CcSEcCtD
Nafarelin—Arthralgia—Prednisone—prostate cancer	8.6e-06	0.000202	CcSEcCtD
Nafarelin—Myalgia—Prednisone—prostate cancer	8.6e-06	0.000202	CcSEcCtD
Nafarelin—Paraesthesia—Docetaxel—prostate cancer	8.58e-06	0.000201	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—ANXA1—prostate cancer	8.57e-06	0.00138	CbGpPWpGaD
Nafarelin—Dyspnoea—Docetaxel—prostate cancer	8.52e-06	0.0002	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Capecitabine—prostate cancer	8.43e-06	0.000198	CcSEcCtD
Nafarelin—Rhinitis—Doxorubicin—prostate cancer	8.42e-06	0.000197	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—PRKCZ—prostate cancer	8.41e-06	0.00136	CbGpPWpGaD
Nafarelin—Insomnia—Capecitabine—prostate cancer	8.37e-06	0.000196	CcSEcCtD
Nafarelin—Paraesthesia—Capecitabine—prostate cancer	8.31e-06	0.000195	CcSEcCtD
Nafarelin—Decreased appetite—Docetaxel—prostate cancer	8.31e-06	0.000195	CcSEcCtD
Nafarelin—Asthenia—Etoposide—prostate cancer	8.25e-06	0.000193	CcSEcCtD
Nafarelin—Dyspnoea—Capecitabine—prostate cancer	8.25e-06	0.000193	CcSEcCtD
Nafarelin—Oedema—Prednisone—prostate cancer	8.25e-06	0.000193	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—PIK3CG—prostate cancer	8.22e-06	0.00133	CbGpPWpGaD
Nafarelin—Nausea—Mitoxantrone—prostate cancer	8.22e-06	0.000193	CcSEcCtD
Nafarelin—Constipation—Docetaxel—prostate cancer	8.18e-06	0.000192	CcSEcCtD
Nafarelin—Pruritus—Etoposide—prostate cancer	8.14e-06	0.000191	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—PARP1—prostate cancer	8.12e-06	0.00131	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—FGFR4—prostate cancer	8.12e-06	0.00131	CbGpPWpGaD
Nafarelin—Shock—Prednisone—prostate cancer	8.11e-06	0.00019	CcSEcCtD
Nafarelin—Decreased appetite—Capecitabine—prostate cancer	8.05e-06	0.000189	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—CALCA—prostate cancer	8.02e-06	0.0013	CbGpPWpGaD
Nafarelin—Alopecia—Epirubicin—prostate cancer	8.02e-06	0.000188	CcSEcCtD
Nafarelin—Hyperhidrosis—Prednisone—prostate cancer	7.97e-06	0.000187	CcSEcCtD
Nafarelin—Mental disorder—Epirubicin—prostate cancer	7.95e-06	0.000186	CcSEcCtD
Nafarelin—Constipation—Capecitabine—prostate cancer	7.92e-06	0.000186	CcSEcCtD
Nafarelin—Malnutrition—Epirubicin—prostate cancer	7.9e-06	0.000185	CcSEcCtD
Nafarelin—Diarrhoea—Etoposide—prostate cancer	7.87e-06	0.000185	CcSEcCtD
Nafarelin—Anorexia—Prednisone—prostate cancer	7.86e-06	0.000184	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—CXCL12—prostate cancer	7.83e-06	0.00127	CbGpPWpGaD
Nafarelin—Tension—Epirubicin—prostate cancer	7.75e-06	0.000182	CcSEcCtD
Nafarelin—Dysgeusia—Epirubicin—prostate cancer	7.74e-06	0.000181	CcSEcCtD
Nafarelin—Nervousness—Epirubicin—prostate cancer	7.67e-06	0.00018	CcSEcCtD
Nafarelin—Dizziness—Etoposide—prostate cancer	7.61e-06	0.000178	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Prednisone—prostate cancer	7.51e-06	0.000176	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—PIK3CG—prostate cancer	7.46e-06	0.00121	CbGpPWpGaD
Nafarelin—Insomnia—Prednisone—prostate cancer	7.46e-06	0.000175	CcSEcCtD
Nafarelin—Alopecia—Doxorubicin—prostate cancer	7.42e-06	0.000174	CcSEcCtD
Nafarelin—Paraesthesia—Prednisone—prostate cancer	7.4e-06	0.000174	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—CASP9—prostate cancer	7.38e-06	0.00119	CbGpPWpGaD
Nafarelin—Mental disorder—Doxorubicin—prostate cancer	7.36e-06	0.000172	CcSEcCtD
Nafarelin—Urticaria—Capecitabine—prostate cancer	7.35e-06	0.000172	CcSEcCtD
Nafarelin—Vomiting—Etoposide—prostate cancer	7.31e-06	0.000171	CcSEcCtD
Nafarelin—Malnutrition—Doxorubicin—prostate cancer	7.31e-06	0.000171	CcSEcCtD
Nafarelin—Rash—Etoposide—prostate cancer	7.25e-06	0.00017	CcSEcCtD
Nafarelin—Dermatitis—Etoposide—prostate cancer	7.25e-06	0.00017	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—PIK3CD—prostate cancer	7.23e-06	0.00117	CbGpPWpGaD
Nafarelin—Headache—Etoposide—prostate cancer	7.21e-06	0.000169	CcSEcCtD
Nafarelin—Tension—Doxorubicin—prostate cancer	7.17e-06	0.000168	CcSEcCtD
Nafarelin—Decreased appetite—Prednisone—prostate cancer	7.17e-06	0.000168	CcSEcCtD
Nafarelin—Dysgeusia—Doxorubicin—prostate cancer	7.16e-06	0.000168	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—NGFR—prostate cancer	7.15e-06	0.00115	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PRKCQ—prostate cancer	7.15e-06	0.00115	CbGpPWpGaD
Nafarelin—Nervousness—Doxorubicin—prostate cancer	7.1e-06	0.000166	CcSEcCtD
Nafarelin—Vertigo—Epirubicin—prostate cancer	7.1e-06	0.000166	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—MAP3K7—prostate cancer	7.06e-06	0.00114	CbGpPWpGaD
Nafarelin—Constipation—Prednisone—prostate cancer	7.05e-06	0.000165	CcSEcCtD
Nafarelin—Palpitations—Epirubicin—prostate cancer	6.98e-06	0.000164	CcSEcCtD
Nafarelin—Asthenia—Docetaxel—prostate cancer	6.86e-06	0.000161	CcSEcCtD
Nafarelin—Convulsion—Epirubicin—prostate cancer	6.85e-06	0.00016	CcSEcCtD
Nafarelin—Nausea—Etoposide—prostate cancer	6.83e-06	0.00016	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—FGF10—prostate cancer	6.79e-06	0.0011	CbGpPWpGaD
Nafarelin—Pruritus—Docetaxel—prostate cancer	6.76e-06	0.000159	CcSEcCtD
Nafarelin—Chest pain—Epirubicin—prostate cancer	6.73e-06	0.000158	CcSEcCtD
Nafarelin—Arthralgia—Epirubicin—prostate cancer	6.73e-06	0.000158	CcSEcCtD
Nafarelin—Myalgia—Epirubicin—prostate cancer	6.73e-06	0.000158	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—ADRB2—prostate cancer	6.72e-06	0.00109	CbGpPWpGaD
Nafarelin—Asthenia—Capecitabine—prostate cancer	6.64e-06	0.000156	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—JAK2—prostate cancer	6.63e-06	0.00107	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—MAP2K1—prostate cancer	6.6e-06	0.00107	CbGpPWpGaD
Nafarelin—Vertigo—Doxorubicin—prostate cancer	6.57e-06	0.000154	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—PIK3CD—prostate cancer	6.56e-06	0.00106	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—VAV3—prostate cancer	6.55e-06	0.00106	CbGpPWpGaD
Nafarelin—Urticaria—Prednisone—prostate cancer	6.55e-06	0.000154	CcSEcCtD
Nafarelin—Pruritus—Capecitabine—prostate cancer	6.55e-06	0.000154	CcSEcCtD
Nafarelin—Diarrhoea—Docetaxel—prostate cancer	6.54e-06	0.000153	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—TGFBR2—prostate cancer	6.46e-06	0.00104	CbGpPWpGaD
Nafarelin—Palpitations—Doxorubicin—prostate cancer	6.46e-06	0.000151	CcSEcCtD
Nafarelin—Oedema—Epirubicin—prostate cancer	6.45e-06	0.000151	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—ITPR1—prostate cancer	6.36e-06	0.00103	CbGpPWpGaD
Nafarelin—Shock—Epirubicin—prostate cancer	6.34e-06	0.000149	CcSEcCtD
Nafarelin—Convulsion—Doxorubicin—prostate cancer	6.33e-06	0.000148	CcSEcCtD
Nafarelin—Diarrhoea—Capecitabine—prostate cancer	6.33e-06	0.000148	CcSEcCtD
Nafarelin—Dizziness—Docetaxel—prostate cancer	6.32e-06	0.000148	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—PIK3CB—prostate cancer	6.3e-06	0.00102	CbGpPWpGaD
Nafarelin—Hyperhidrosis—Epirubicin—prostate cancer	6.23e-06	0.000146	CcSEcCtD
Nafarelin—Myalgia—Doxorubicin—prostate cancer	6.22e-06	0.000146	CcSEcCtD
Nafarelin—Arthralgia—Doxorubicin—prostate cancer	6.22e-06	0.000146	CcSEcCtD
Nafarelin—Chest pain—Doxorubicin—prostate cancer	6.22e-06	0.000146	CcSEcCtD
Nafarelin—Anorexia—Epirubicin—prostate cancer	6.15e-06	0.000144	CcSEcCtD
Nafarelin—Dizziness—Capecitabine—prostate cancer	6.12e-06	0.000143	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—IGF1R—prostate cancer	6.08e-06	0.000982	CbGpPWpGaD
Nafarelin—Vomiting—Docetaxel—prostate cancer	6.08e-06	0.000142	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—CXCL8—prostate cancer	6.05e-06	0.000978	CbGpPWpGaD
Nafarelin—Rash—Docetaxel—prostate cancer	6.03e-06	0.000141	CcSEcCtD
Nafarelin—Dermatitis—Docetaxel—prostate cancer	6.02e-06	0.000141	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—JAK2—prostate cancer	6.02e-06	0.000973	CbGpPWpGaD
Nafarelin—Headache—Docetaxel—prostate cancer	5.99e-06	0.00014	CcSEcCtD
Nafarelin—Oedema—Doxorubicin—prostate cancer	5.97e-06	0.00014	CcSEcCtD
Nafarelin—Asthenia—Prednisone—prostate cancer	5.92e-06	0.000139	CcSEcCtD
Nafarelin—Vomiting—Capecitabine—prostate cancer	5.89e-06	0.000138	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Epirubicin—prostate cancer	5.88e-06	0.000138	CcSEcCtD
Nafarelin—Shock—Doxorubicin—prostate cancer	5.87e-06	0.000138	CcSEcCtD
Nafarelin—Rash—Capecitabine—prostate cancer	5.84e-06	0.000137	CcSEcCtD
Nafarelin—Pruritus—Prednisone—prostate cancer	5.83e-06	0.000137	CcSEcCtD
Nafarelin—Insomnia—Epirubicin—prostate cancer	5.83e-06	0.000137	CcSEcCtD
Nafarelin—Dermatitis—Capecitabine—prostate cancer	5.83e-06	0.000137	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—LPL—prostate cancer	5.83e-06	0.000942	CbGpPWpGaD
Nafarelin—Headache—Capecitabine—prostate cancer	5.8e-06	0.000136	CcSEcCtD
Nafarelin—Paraesthesia—Epirubicin—prostate cancer	5.79e-06	0.000136	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—IL2—prostate cancer	5.78e-06	0.000934	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PDGFRB—prostate cancer	5.78e-06	0.000933	CbGpPWpGaD
Nafarelin—Hyperhidrosis—Doxorubicin—prostate cancer	5.77e-06	0.000135	CcSEcCtD
Nafarelin—Dyspnoea—Epirubicin—prostate cancer	5.75e-06	0.000135	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—PIK3CB—prostate cancer	5.72e-06	0.000924	CbGpPWpGaD
Nafarelin—Anorexia—Doxorubicin—prostate cancer	5.69e-06	0.000133	CcSEcCtD
Nafarelin—Nausea—Docetaxel—prostate cancer	5.68e-06	0.000133	CcSEcCtD
Nafarelin—Diarrhoea—Prednisone—prostate cancer	5.64e-06	0.000132	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—ITGB3—prostate cancer	5.63e-06	0.000909	CbGpPWpGaD
Nafarelin—Decreased appetite—Epirubicin—prostate cancer	5.61e-06	0.000131	CcSEcCtD
Nafarelin—Constipation—Epirubicin—prostate cancer	5.51e-06	0.000129	CcSEcCtD
Nafarelin—Nausea—Capecitabine—prostate cancer	5.5e-06	0.000129	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—CXCL8—prostate cancer	5.5e-06	0.000888	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—ERBB3—prostate cancer	5.46e-06	0.000882	CbGpPWpGaD
Nafarelin—Dizziness—Prednisone—prostate cancer	5.45e-06	0.000128	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—FGFR2—prostate cancer	5.45e-06	0.000881	CbGpPWpGaD
Nafarelin—Musculoskeletal discomfort—Doxorubicin—prostate cancer	5.44e-06	0.000127	CcSEcCtD
Nafarelin—Insomnia—Doxorubicin—prostate cancer	5.4e-06	0.000127	CcSEcCtD
Nafarelin—Paraesthesia—Doxorubicin—prostate cancer	5.36e-06	0.000126	CcSEcCtD
Nafarelin—Dyspnoea—Doxorubicin—prostate cancer	5.32e-06	0.000125	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—IL2—prostate cancer	5.25e-06	0.000848	CbGpPWpGaD
Nafarelin—Vomiting—Prednisone—prostate cancer	5.24e-06	0.000123	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—TERT—prostate cancer	5.23e-06	0.000845	CbGpPWpGaD
Nafarelin—Rash—Prednisone—prostate cancer	5.2e-06	0.000122	CcSEcCtD
Nafarelin—Dermatitis—Prednisone—prostate cancer	5.19e-06	0.000122	CcSEcCtD
Nafarelin—Decreased appetite—Doxorubicin—prostate cancer	5.19e-06	0.000122	CcSEcCtD
Nafarelin—Headache—Prednisone—prostate cancer	5.17e-06	0.000121	CcSEcCtD
Nafarelin—Urticaria—Epirubicin—prostate cancer	5.12e-06	0.00012	CcSEcCtD
Nafarelin—Constipation—Doxorubicin—prostate cancer	5.1e-06	0.00012	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—HIF1A—prostate cancer	5e-06	0.000808	CbGpPWpGaD
Nafarelin—Nausea—Prednisone—prostate cancer	4.9e-06	0.000115	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—LEP—prostate cancer	4.89e-06	0.000789	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CAV1—prostate cancer	4.84e-06	0.000782	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—KDR—prostate cancer	4.79e-06	0.000773	CbGpPWpGaD
Nafarelin—Urticaria—Doxorubicin—prostate cancer	4.74e-06	0.000111	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—ESR1—prostate cancer	4.66e-06	0.000753	CbGpPWpGaD
Nafarelin—Asthenia—Epirubicin—prostate cancer	4.63e-06	0.000108	CcSEcCtD
Nafarelin—Pruritus—Epirubicin—prostate cancer	4.56e-06	0.000107	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—BAD—prostate cancer	4.55e-06	0.000735	CbGpPWpGaD
Nafarelin—Diarrhoea—Epirubicin—prostate cancer	4.41e-06	0.000103	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—APC—prostate cancer	4.41e-06	0.000712	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PIK3CG—prostate cancer	4.41e-06	0.000712	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—EGF—prostate cancer	4.36e-06	0.000704	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—IRS1—prostate cancer	4.36e-06	0.000704	CbGpPWpGaD
Nafarelin—Asthenia—Doxorubicin—prostate cancer	4.28e-06	0.0001	CcSEcCtD
Nafarelin—Dizziness—Epirubicin—prostate cancer	4.26e-06	0.0001	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—GSK3B—prostate cancer	4.23e-06	0.000683	CbGpPWpGaD
Nafarelin—Pruritus—Doxorubicin—prostate cancer	4.22e-06	9.9e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—INS—prostate cancer	4.17e-06	0.000674	CbGpPWpGaD
Nafarelin—Vomiting—Epirubicin—prostate cancer	4.1e-06	9.61e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—CREBBP—prostate cancer	4.09e-06	0.00066	CbGpPWpGaD
Nafarelin—Diarrhoea—Doxorubicin—prostate cancer	4.08e-06	9.57e-05	CcSEcCtD
Nafarelin—Rash—Epirubicin—prostate cancer	4.07e-06	9.53e-05	CcSEcCtD
Nafarelin—Dermatitis—Epirubicin—prostate cancer	4.06e-06	9.52e-05	CcSEcCtD
Nafarelin—Headache—Epirubicin—prostate cancer	4.04e-06	9.47e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—IGF1—prostate cancer	4.04e-06	0.000652	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—EGFR—prostate cancer	4.02e-06	0.000649	CbGpPWpGaD
Nafarelin—Dizziness—Doxorubicin—prostate cancer	3.95e-06	9.25e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—MAP2K1—prostate cancer	3.9e-06	0.00063	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PIK3CD—prostate cancer	3.88e-06	0.000626	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—PIK3CA—prostate cancer	3.84e-06	0.00062	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—SERPINE1—prostate cancer	3.83e-06	0.000619	CbGpPWpGaD
Nafarelin—Nausea—Epirubicin—prostate cancer	3.83e-06	8.98e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—KRAS—prostate cancer	3.79e-06	0.000613	CbGpPWpGaD
Nafarelin—Vomiting—Doxorubicin—prostate cancer	3.79e-06	8.89e-05	CcSEcCtD
Nafarelin—Rash—Doxorubicin—prostate cancer	3.76e-06	8.82e-05	CcSEcCtD
Nafarelin—Dermatitis—Doxorubicin—prostate cancer	3.76e-06	8.81e-05	CcSEcCtD
Nafarelin—Headache—Doxorubicin—prostate cancer	3.74e-06	8.76e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—FGF2—prostate cancer	3.71e-06	0.0006	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—NOS3—prostate cancer	3.66e-06	0.000591	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—JAK2—prostate cancer	3.56e-06	0.000575	CbGpPWpGaD
Nafarelin—Nausea—Doxorubicin—prostate cancer	3.54e-06	8.31e-05	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—PIK3CA—prostate cancer	3.49e-06	0.000563	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MDM2—prostate cancer	3.47e-06	0.000561	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—ERBB2—prostate cancer	3.42e-06	0.000553	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PIK3CB—prostate cancer	3.38e-06	0.000546	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CXCL8—prostate cancer	3.25e-06	0.000524	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CDKN1B—prostate cancer	3.17e-06	0.000512	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—AKT1—prostate cancer	3.14e-06	0.000507	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CASP3—prostate cancer	3.11e-06	0.000502	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—IL2—prostate cancer	3.1e-06	0.000501	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—IL6—prostate cancer	3.09e-06	0.000499	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CCND1—prostate cancer	3.02e-06	0.000489	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CTNNB1—prostate cancer	3e-06	0.000484	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MMP9—prostate cancer	2.94e-06	0.000474	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CDKN1A—prostate cancer	2.93e-06	0.000473	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PTEN—prostate cancer	2.92e-06	0.000472	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—AKT1—prostate cancer	2.85e-06	0.00046	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—EP300—prostate cancer	2.78e-06	0.00045	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—SRC—prostate cancer	2.71e-06	0.000437	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—VEGFA—prostate cancer	2.64e-06	0.000426	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—STAT3—prostate cancer	2.61e-06	0.000422	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MYC—prostate cancer	2.43e-06	0.000392	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—TGFB1—prostate cancer	2.42e-06	0.000391	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—EGFR—prostate cancer	2.37e-06	0.000383	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—KRAS—prostate cancer	2.24e-06	0.000362	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PIK3CA—prostate cancer	2.06e-06	0.000333	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—TP53—prostate cancer	1.99e-06	0.000322	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—IL6—prostate cancer	1.82e-06	0.000295	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—AKT1—prostate cancer	1.68e-06	0.000272	CbGpPWpGaD
